Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

2-34. (canceled)

A pharmaceutical composition comprising an infectious, replication-deficient arenavirus particle, a chemotherapeutic agent and a pharmaceutically acceptable carrier, wherein said arenavirus particle is engineered to contain a genome comprising:

• a. a nucleotide sequence encoding a tumor antigen, tumor associated antigen or an antigenic fragment thereof;
• and
• b. the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in non-complementing cells.

36-60. (canceled)

A kit comprising two or more containers and instructions for use, wherein one of said containers comprises an infectious, replication-deficient arenavirus particle and another of said containers comprises an chemotherapeutic agent, wherein said arenavirus particle is engineered to contain a genome comprising:

• a. a nucleotide sequence encoding a tumor antigen, tumor associated antigen or an antigenic fragment thereof;
• and
• b. the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in non-complementing cells.

63-87. (canceled)

A method for treating a neoplastic disease in a subject comprising, administering to a subject in need thereof an arenavirus particle and a chemotherapeutic agent, wherein said arenavirus particle is a tri-segmented arenavirus particle comprising one L segment and two S segments, and wherein said arenavirus particle is engineered to contain an arenavirus genomic segment comprising:

• (i) a nucleotide sequence encoding a tumor antigen, tumor associated antigen or an antigenic fragment thereof;
• and
• (ii) at least one arenavirus open reading frame (“ORF”) in a position other than the wild-type position of said ORF, wherein said ORF encodes the glycoprotein (“GP”), the nucleoprotein (“NP”), the matrix protein Z (“Z protein”) or the RNA dependent RNA polymerase L (“L protein”) of said arenavirus particle.

(canceled)

(canceled)

(canceled)

97-98. (canceled)

(canceled)

103-119. (canceled)

121-122. (canceled)

(canceled)

(canceled)

128-133. (canceled)

A pharmaceutical composition comprising an arenavirus particle, a chemotherapeutic agent and a pharmaceutically acceptable carrier, wherein said arenavirus particle is a tri-segmented arenavirus particle comprising one L segment and two S segments, and wherein said arenavirus particle is engineered to contain an arenavirus genomic segment comprising:

• (i) a nucleotide sequence encoding a tumor antigen, tumor associated antigen or an antigenic fragment thereof;
• and
• (ii) at least one arenavirus open reading frame (“ORF”) in a position other than the wild-type position of said ORF, wherein said ORF encodes the glycoprotein (“GP”), the nucleoprotein (“NP”), the matrix protein Z (“Z protein”) or the RNA dependent RNA polymerase L (“L protein”) of said arenavirus particle.

139-140. (canceled)

(canceled)

144-160. (canceled)

162-163. (canceled)

(canceled)

(canceled)

(canceled)

171-177. (canceled)

(canceled)

A kit comprising two or more containers and instructions for use, wherein one of said containers comprises an arenavirus particle and another of said containers comprises a chemotherapeutic agent, wherein said arenavirus particle is a tri segmented arenavirus particle comprising one L segment and two S segments, and wherein said arenavirus particle is engineered to contain an arenavirus genomic segment comprising:

• (i) a nucleotide sequence encoding a tumor antigen, tumor associated antigen or an antigenic fragment thereof;
• and
• (ii) at least one arenavirus open reading frame (“ORF”) in a position other than the wild-type position of said ORF, wherein said ORF encodes the glycoprotein (“GP”), the nucleoprotein (“NP”), the matrix protein Z (“Z protein”) or the RNA dependent RNA polymerase L (“L protein”) of said arenavirus particle.

182-221. (canceled)